Form 13-F position report

KINTARA THERAPEUTICS INC

Reported by STATE STREET CORPORATION

KTRA CUSIP 49720K101 Manager CIK 0000093751

Reported 116,074 shares, unchanged from the prior quarter.

Reported value -30.4%; share count 0.0% vs. the prior quarter.

Unchanged
% of reported 13F value < 0.01% This manager · Q2 2022
Shares 116,074 Quarter-end amount reported
Reported value $32,000 Fair value at quarter end
Consecutive quarters held 8 Through Q2 2022

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-12-31 59000
2022-03-31 46000
2022-06-30 32000
2022-09-30 13000
2022-12-31 0
2022-12-31 73868
2023-03-31 39453
2023-06-30 43206
2023-09-30 43420
2023-12-31 1818
2024-03-31 1115
2024-06-30 2896
2024-09-30 2091
2024-12-31 0

Quarterly position history

How this manager's reported quarter-end position changed over time.

14 quarters
Quarterly reported position history for KINTARA THERAPEUTICS INC held by STATE STREET CORPORATION.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q4 2024 Reduced 0 -10,721 (-100.0%) 0 $0 2025-02-14
Q3 2024 Unchanged 10,721 0 (0.0%) < 0.01% $2,091 2024-11-14
Q2 2024 Unchanged 10,721 0 (0.0%) < 0.01% $2,896 2024-08-14
Q1 2024 Unchanged 10,721 0 (0.0%) < 0.01% $1,115 2024-05-15
Q4 2023 Unchanged 10,721 0 (0.0%) < 0.01% $1,818 2024-02-14
Q3 2023 Unchanged 10,721 0 (0.0%) < 0.01% $43,420 2023-11-14
Q2 2023 Unchanged 10,721 0 (0.0%) < 0.01% $43,206 2023-08-14
Q1 2023 Unchanged 10,721 0 (0.0%) < 0.01% $39,453 2023-05-15
Q4 2022 New 10,721 +10,721 (0.0%) < 0.01% $73,868 2023-02-14
Q4 2022 Reduced 0 -116,074 (-100.0%) 0 $0 2023-02-14
Q3 2022 Unchanged 116,074 0 (0.0%) < 0.01% $13,000 2022-11-15
Q2 2022 Unchanged 116,074 0 (0.0%) < 0.01% $32,000 2022-08-15
Q1 2022 Unchanged 116,074 0 (0.0%) < 0.01% $46,000 2022-05-16
Q4 2021 Unchanged 116,074 0 (0.0%) < 0.01% $59,000 2022-02-14
Five years are shown. A free account unlocks the complete reported history. Unlock full history

Who else reported the position

30 managers reported KINTARA THERAPEUTICS INC for Q2 2022.

Managers reporting KINTARA THERAPEUTICS INC in Q2 2022.
Manager Activity Shares Change % of reported 13F Reported value Tenure
VANGUARD GROUP INC Unchanged 1,417,482 0 < 0.01% $394,000 8 qtrs
RENAISSANCE TECHNOLOGIES LLC Added 722,400 +667,284 < 0.01% $201,000 3 qtrs
GEODE CAPITAL MANAGEMENT LLC Reduced 358,026 -210,393 < 0.01% $99,000 6 qtrs
swisspartners Ltd Unchanged 275,000 0 0.08% $79,000 6 qtrs
ACADIAN ASSET MANAGEMENT LLC New 207,114 +207,114 < 0.01% $58,000 1 qtr
Nantahala Capital Management LLC Reduced 116,234 -547,045 < 0.01% $32,000 7 qtrs
STATE STREET CORPORATION This report Unchanged 116,074 0 < 0.01% $32,000 8 qtrs
MILLENNIUM MANAGEMENT LLC Added 54,153 +40,255 < 0.01% $15,000 2 qtrs
ADVISOR GROUP HOLDINGS INC Reduced 48,175 -25,192 < 0.01% $13,000 6 qtrs
NORTHERN TRUST CORPORATION Unchanged 44,142 0 < 0.01% $12,000 8 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
June 30, 2022
Filed
August 15, 2022
Filing type
13F-HR
Position type
COM

Voting authority reported

Sole
116,074
Shared
0
None
0

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.